메뉴 건너뛰기




Volumn 32, Issue 3, 2002, Pages 188-193

Treatment of dyslipidaemia in the elderly

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; AUSGEM; CERIVASTATIN; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GEMHEXAL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; JEZIL; LIPAZIL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; PROTEINASE INHIBITOR; RESIN; SIMVASTATIN; TRIACYLGLYCEROL;

EID: 0036760984     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jppr2002323188     Document Type: Review
Times cited : (2)

References (39)
  • 1
    • 0026736470 scopus 로고
    • Hyperlipidaemia and the aged
    • Cohen N, Gilbert R. Hyperlipidaemia and the aged. Aust J Hosp Pharm 1992; 22: 238-43.
    • (1992) Aust J Hosp Pharm , vol.22 , pp. 238-243
    • Cohen, N.1    Gilbert, R.2
  • 2
    • 0035873251 scopus 로고    scopus 로고
    • Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial
    • Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 2001; 134: 931-40.
    • (2001) Ann Intern Med , vol.134 , pp. 931-940
    • Hunt, D.1    Young, P.2    Simes, J.3    Hague, W.4    Mann, S.5    Owensby, D.6
  • 3
    • 1542327997 scopus 로고    scopus 로고
    • Lipid management guidelines - 2001
    • National Heart Foundation of Australia, CSANZ
    • Lipid management guidelines - 2001. National Heart Foundation of Australia, CSANZ. Med J Aust 2001; 175 (suppl.): S57-S85.
    • (2001) Med J Aust , vol.175 , Issue.SUPPL.
  • 4
    • 8544236713 scopus 로고    scopus 로고
    • Canberra: Commonwealth of Australia; (May)
    • Schedule of Pharmaceutical Benefits. Canberra: Commonwealth of Australia; 2002 (May).
    • (2002) Schedule of Pharmaceutical Benefits
  • 5
    • 0035813340 scopus 로고    scopus 로고
    • Lipid lowering and coronary heart disease risk: How appropriate are the national guidelines?
    • Forge BH, Briganti EM. Lipid lowering and coronary heart disease risk: How appropriate are the national guidelines? Med J Aust 2001; 175: 471-5.
    • (2001) Med J Aust , vol.175 , pp. 471-475
    • Forge, B.H.1    Briganti, E.M.2
  • 6
    • 0035813357 scopus 로고    scopus 로고
    • Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria
    • Lim SS, Vos T, Peeters A, Liew D, McNeil JJ, Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria. Med J Aust 2001; 175: 459-64.
    • (2001) Med J Aust , vol.175 , pp. 459-464
    • Lim, S.S.1    Vos, T.2    Peeters, A.3    Liew, D.4    McNeil, J.J.5
  • 7
    • 0028883828 scopus 로고
    • Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
    • West of Scotland Coronary Prevention Study Group
    • Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.
    • (1995) N Engl J Med , vol.333 , pp. 1301-1307
    • Shepherd, J.1    Cobbe, S.M.2    Ford, I.3    Isles, C.G.4    Lorimer, A.R.5    MacFarlane, P.W.6
  • 8
    • 0032572086 scopus 로고    scopus 로고
    • Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
    • Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
    • (1998) JAMA , vol.279 , pp. 1615-1622
    • Downs, J.R.1    Clearfield, M.2    Weis, S.3    Whitney, E.4    Shapiro, D.R.5    Beere, P.A.6
  • 9
    • 0344653659 scopus 로고    scopus 로고
    • Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S)
    • Miettinen TA, Pyorala K, Olsson AG, Musliner TA, Cook TJ. Faergeman O, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997; 96: 4211-8.
    • (1997) Circulation , vol.96 , pp. 4211-4218
    • Miettinen, T.A.1    Pyorala, K.2    Olsson, A.G.3    Musliner, T.A.4    Cook, T.J.5    Faergeman, O.6
  • 10
    • 14444271787 scopus 로고    scopus 로고
    • Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the CARE trial
    • Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the CARE trial. Ann Intern Med 1998; 129: 681-9.
    • (1998) Ann Intern Med , vol.129 , pp. 681-689
    • Lewis, S.J.1    Moye, L.A.2    Sacks, F.M.3    Johnstone, D.E.4    Timmis, G.5    Mitchell, J.6
  • 11
    • 0032487931 scopus 로고    scopus 로고
    • Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
    • The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
    • (1998) N Engl J Med , vol.339 , pp. 1349-1357
  • 12
    • 0035806734 scopus 로고    scopus 로고
    • Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: A cohort study
    • Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: A cohort study. Lancet 2001; 358: 351-5.
    • (2001) Lancet , vol.358 , pp. 351-355
    • Schatz, I.J.1    Masaki, K.2    Yano, K.3    Chen, R.4    Rodriguez, B.L.5    Curb, J.D.6
  • 14
    • 0034680352 scopus 로고    scopus 로고
    • Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin Pooling Project
    • Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin Pooling Project. Circulation 2000; 102: 1893-900.
    • (2000) Circulation , vol.102 , pp. 1893-1900
    • Sacks, F.M.1    Tonkin, A.M.2    Shepherd, J.3    Braunwald, E.4    Cobbe, S.5    Hawkins, C.M.6
  • 15
    • 0035923818 scopus 로고    scopus 로고
    • American Heart Association 2001 scientific sessions: Late-breaking science-statins: The new aspirin?
    • Fox R. American Heart Association 2001 scientific sessions: Late-breaking science-statins: The new aspirin? Circulation 2001; 104: E9051-2.
    • (2001) Circulation , vol.104
    • Fox, R.1
  • 16
    • 0037031061 scopus 로고    scopus 로고
    • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: A randomised placebo-controlled trial
    • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
    • (2002) Lancet , vol.360 , pp. 7-22
  • 17
    • 0037046204 scopus 로고    scopus 로고
    • Secondary prevention of coronary heart disease in the elderly (with emphasis on patients ≥75 years of age). An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise. Cardiac rehabilitation, and prevention
    • Williams MA, Fleg JL, Ades PA, Chairman BR, Miller NH, Mohiuddin SM, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients ≥75 years of age). An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise. Cardiac rehabilitation, and prevention. Circulation 2002; 105: 1735-43.
    • (2002) Circulation , vol.105 , pp. 1735-1743
    • Williams, M.A.1    Fleg, J.L.2    Ades, P.A.3    Chairman, B.R.4    Miller, N.H.5    Mohiuddin, S.M.6
  • 18
    • 0037166649 scopus 로고    scopus 로고
    • Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: Evidence from the Cardiovascular Health Study
    • Lemaitre RN, Psacy BM, Heckbert SR, Kronmal RA, Newman AB, Burke GL. Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: Evidence from the Cardiovascular Health Study. Arch Intern Med 2002; 162: 1395-400.
    • (2002) Arch Intern Med , vol.162 , pp. 1395-1400
    • Lemaitre, R.N.1    Psacy, B.M.2    Heckbert, S.R.3    Kronmal, R.A.4    Newman, A.B.5    Burke, G.L.6
  • 19
    • 0036147374 scopus 로고    scopus 로고
    • Risk factors for acute myocardial infarction in the elderly (the Dubbo study)
    • Simons LA, Simons J, Friedlander Y, McCallum J. Risk factors for acute myocardial infarction in the elderly (the Dubbo study). Am J Cardiol 2002; 89: 69-72.
    • (2002) Am J Cardiol , vol.89 , pp. 69-72
    • Simons, L.A.1    Simons, J.2    Friedlander, Y.3    McCallum, J.4
  • 20
    • 0023232216 scopus 로고
    • Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
    • Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease, N Engl J Med 1987; 317: 1237-45.
    • (1987) N Engl J Med , vol.317 , pp. 1237-1245
    • Frick, M.H.1    Elo, O.2    Haapa, K.3    Heinonen, O.P.4    Heinsalmi, P.5    Helo, P.6
  • 21
    • 0033527030 scopus 로고    scopus 로고
    • Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
    • Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
    • Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-8.
    • (1999) N Engl J Med , vol.341 , pp. 410-418
    • Rubins, H.B.1    Robins, S.J.2    Collins, D.3    Fye, C.L.4    Anderson, J.W.5    Elam, M.B.6
  • 22
    • 0035897696 scopus 로고    scopus 로고
    • Executive summary of the third report of The National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    • Executive summary of the third report of The National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
    • (2001) JAMA , vol.285 , pp. 2486-2497
  • 23
    • 0037166646 scopus 로고    scopus 로고
    • Statin therapy in older persons: Pertinent issues
    • Grundy SM. Statin therapy in older persons: Pertinent issues. Arch Intern Med 2002; 162: 1329-31.
    • (2002) Arch Intern Med , vol.162 , pp. 1329-1331
    • Grundy, S.M.1
  • 24
    • 0030604595 scopus 로고    scopus 로고
    • 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia
    • Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand
    • 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand. NZ Med J 1996; 109: 224-31.
    • (1996) NZ Med J , vol.109 , pp. 224-231
  • 26
    • 0034673940 scopus 로고    scopus 로고
    • Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction
    • Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med 2000; 132: 780-7.
    • (2000) Ann Intern Med , vol.132 , pp. 780-787
    • Ganz, D.A.1    Kuntz, K.M.2    Jacobson, G.A.3    Avorn, J.4
  • 27
    • 0037185430 scopus 로고    scopus 로고
    • Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: The DVA High-Density Lipoprotein Cholesterol Intervention Trial
    • Nyman JA, Martinson MS, Nelson D, Nugent S, Collins D, Wittes J, et al. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: The DVA High-Density Lipoprotein Cholesterol Intervention Trial. Arch Intern Med 2002; 162: 177-82.
    • (2002) Arch Intern Med , vol.162 , pp. 177-182
    • Nyman, J.A.1    Martinson, M.S.2    Nelson, D.3    Nugent, S.4    Collins, D.5    Wittes, J.6
  • 29
    • 0033995230 scopus 로고    scopus 로고
    • Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice
    • Barter PJ, O'Brien RC. Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice. Atherosclerosis 2000; 149: 199-205.
    • (2000) Atherosclerosis , vol.149 , pp. 199-205
    • Barter, P.J.1    O'Brien, R.C.2
  • 30
    • 0035804846 scopus 로고    scopus 로고
    • Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial
    • Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001; 285: 1711-8.
    • (2001) JAMA , vol.285 , pp. 1711-1718
    • Schwartz, G.G.1    Olsson, A.G.2    Ezekowitz, M.D.3    Ganz, P.4    Oliver, M.F.5    Waters, D.6
  • 33
    • 0036186663 scopus 로고    scopus 로고
    • Serum lipoprotein levels, statin use, and cognitive function in older women
    • Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002; 59: 378-84.
    • (2002) Arch Neurol , vol.59 , pp. 378-384
    • Yaffe, K.1    Barrett-Connor, E.2    Lin, F.3    Grady, D.4
  • 35
    • 0018117095 scopus 로고
    • A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators
    • A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 1978; 40: 1069-118.
    • (1978) Br Heart J , vol.40 , pp. 1069-1118
  • 36
    • 0034604225 scopus 로고    scopus 로고
    • Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study
    • Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study, Circulation 2000; 102: 21-27.
    • (2000) Circulation , vol.102 , pp. 21-27
  • 37
    • 0034644442 scopus 로고    scopus 로고
    • Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT study: A randomized trial
    • Arterial Disease Multiple Intervention Trial
    • Elarn MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000; 284: 1263-70.
    • (2000) JAMA , vol.284 , pp. 1263-1270
    • Elarn, M.B.1    Hunninghake, D.B.2    Davis, K.B.3    Garg, R.4    Johnson, C.5    Egan, D.6
  • 38
    • 0035969564 scopus 로고    scopus 로고
    • Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
    • Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-92.
    • (2001) N Engl J Med , vol.345 , pp. 1583-1592
    • Brown, B.G.1    Zhao, X.Q.2    Chait, A.3    Fisher, L.D.4    Cheung, M.C.5    Morse, J.S.6
  • 39
    • 0037083071 scopus 로고    scopus 로고
    • Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events
    • Taher TH, Dzavik V, Reteff EM, Pearson GJ, Woloschuk BL, Francis GA. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. Am J Cardiol 2002; 89: 3904.
    • (2002) Am J Cardiol , vol.89 , pp. 3904
    • Taher, T.H.1    Dzavik, V.2    Reteff, E.M.3    Pearson, G.J.4    Woloschuk, B.L.5    Francis, G.A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.